Please login to the form below

Not currently logged in
Email:
Password:

Kite’s new CAR T-cell therapy manufacturing facility given the go-ahead by the FDA

The site in the US will produce CAR T-cell therapies for patients with blood cancers

Kite

Kite, a Gilead Company, has announced that the US Food and Drug Administration (FDA) has approved the launch of commercial production at its new CAR T-cell therapy manufacturing facility.

The site, situated in the US, is set to produce Kite’s FDA-approved CAR T-cell therapy used to treat blood cancers.

The site adds to Kite’s existing manufacturing facilities in the US and the Netherlands, forming the largest, dedicated in-house cell therapy manufacturing network in the world.

It covers process development, clinical trial production, vector manufacturing and commercial product manufacturing.

Following the FDA’s commercial production approval, Kite has estimated that its network capacity will be increased by 50%, allowing further patients to be assessed now and in the future.

“The FDA approval of our site marks an important milestone within our global CAR T-cell therapy manufacturing network, and will enable us to significantly expand our production capacity and further strengthen our ability to meet the needs of people living with difficult-to-treat blood cancers,” said Christi Shaw, CEO of Kite.

She added: “Manufacturing is central to every decision we make at Kite. Our teams hold patients’ cells in their hands every day, which could mean the difference between getting a chance to live or possibly losing their battle with cancer. It must be fast and extremely high quality to give patients the best outcome.”

CAR T-cell therapy is unlike other cancer treatments as it is a one-time treatment. The therapies are individually made for each patient, using their own T-cells extracted from their white blood cells. The process involves sending the patient’s T-cells to Kite’s manufacturing facilities where they are modified with a Chimeric Antigen Receptor (CAR) to identify and destroy their cancer cells.

The company started building the facility in 2019 and, although the site has unfinished space, it has allowed for future capacity which will be available to accommodate potential new scientific advances in cell therapy.

Article by
Fleur Jeffries

21st April 2022

From: Regulatory

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Medscape Education Global

Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide....

Latest intelligence

6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
Omnichannel strategies to revolutionize the healthcare professional experience
Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the...
The digital-first launch: the key to connected stakeholder experiences?
During the COVID-19 pandemic, a new digital-first launch model emerged as a gamechanger for driving better customer experiences. Here, Senior Consultant Srividya Sekar; Senior Associate Consultant, Erin Johnstone; and Associate...